Previous 10 | Next 10 |
AcelRx Pharmaceuticals (ACRX) has reached an agreement with the FDA with regards to finalizing corrective actions it has taken or plans to take in response to the previous FDA warning letter, dated February 11, 2021, regarding certain DSUVIA promotional materials. The FDA has agreed with...
AcelRx Announces Agreement with FDA Addressing the Warning Letter Received for DSUVIA® Promotional Materials PR Newswire HAYWARD, Calif. , June 17, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical co...
Ondas Holdings (ONDS) -17% after securing $44.8M capital via equity raise.CEL-SCI (CVM) -12% after securing $31.7M capital raise.UiPath (PATH) -10% on Q1 earnings release.United Natural Foods (UNFI) -9% on FQ3 earnings release.Eastman Kodak (KODK) -10%....
Rapid Discharge with Minimal PACU Opioids was Key Message During Presentation of DSUVIA® For Analgesia in Plastic Surgery Procedures at the California Society of Plastic Surgeons Annual Meeting PR Newswire HAYWARD, Calif. , June 1, 2021 /PRNewswire/ -- ...
4Q20 and 1Q21 DSUVIA sales were down significantly due to COVID-related limitations in hospital activity. Issued shares count stands at 113 million. But business is picking up - and so is the interest in DSUVIA, confirming the excellent prospects. For further details see: ...
Presentation on the Use of DSUVIA® for Plastic Surgery Procedures Selected for "Best Papers" Session at the California Society of Plastic Surgeons Annual Meeting PR Newswire HAYWARD, Calif. , May 26, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Na...
AcelRx Pharmaceuticals recently reported their Q1 earnings with EPS coming in line with the Street’s expectations, but they reported a big miss on revenue. Despite the miss on revenue, I am feeling bullish about ACRX due to the increase in elective surgeries that should help wi...
AcelRx Pharmaceuticals ([[ACRX]]) announces an investigator-initiated study to be conducted at Tampa General Hospital to evaluate the use of DSUVIA for patients with sickle cell disease. The study will enroll 100 patients presenting to the emergency department ((ED)) with vaso-occlusive crisi...
AcelRx Announces an Investigator-Initiated Study of DSUVIA® in the Emergency Department for Patients with Sickle Cell Disease PR Newswire HAYWARD, Calif. , May 20, 2021 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty p...
3 Biotech Penny Stocks to Buy [Or Sell] Today As we approach the end of May, biotech penny stocks are on fire. While there is no one reason for these penny stocks to be seeing sizable gains, we can attribute it to a few potential factors. On one hand, the entire list of penny ...
News, Short Squeeze, Breakout and More Instantly...
AcelRx Pharmaceuticals Inc. Company Name:
ACRX Stock Symbol:
NASDAQ Market:
AcelRx Pharmaceuticals Inc. Website:
AcelRx Announces Rebranding With Name Change to Talphera, Inc. PR Newswire Name change to "Talphera" reflects a new era of the Company in partnership with the medical community developing novel solutions for medically supervised settings Talphera will begin trading on ...
AcelRx Pharmaceuticals Announces Publication of Study Evaluating Anticoagulation Practices for Continuous Renal Replacement Therapy in the United States PR Newswire Use of CRRT increased during COVID and remained at these higher utilization levels Study results demonst...
AcelRx Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Niyad™ Investigational Device Exemption (IDE) approval by the FDA achieved in third quarter Company plans to begin its Niyad registrational study this quarter with topl...